3D Bioprinting

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug CandidatesOrganovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused…

2 years ago
Meeting The Challenges Of BioprintingMeeting The Challenges Of Bioprinting

Meeting The Challenges Of Bioprinting

3D bioprinting offers opportunities such as testing treatment for diseases using artificially affected tissues, and through using bioink, it’s much…

5 years ago